Dublin, Ireland-December 14th, 2009
ICON plc has expanded its European Central Laboratory, located in South County Business Park, Dublin. The newly-designed 41,000 sq ft (3,800m²) facility, which is three times the size of the previous laboratory, provides centralized testing and site support services to clinical investigators in over 70 countries throughout Europe, Middle East, and Africa.
The new laboratory incorporates enhanced automation which is intended to enable reductions in turn-around time for sample testing and reporting, and according to the company, has quadrupled the laboratory’s sample management and storage capacity. In addition, the larger facility has enabled the introduction of new platforms to enhance ICON’s test menu in specialized areas including microbiology, molecular diagnostics, flow cytometry, endocrinology, and RIA. New laboratories have also been created in an effort to accommodate more specialized testing services in the areas of anatomic pathology, molecular diagnostics, and multiplex assays, which will be operational in early 2010.
“Efficient sample management and reporting, and providing an extensive test menu are key fundamentals of any laboratory,” commented Peter Gray, CEO at ICON plc. “The extra capacity in our Dublin laboratory enables ICON to extend our capabilities to support clients’ demands for more sophisticated testing.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.